Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 17;28(2):1262-1273.
doi: 10.3390/curroncol28020120.

Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience

Adnan Zaidi  1 , Amal Khan  2 , Claire Duval  2 , Kamal Haider  1 , Osama Ahmed  1 , Dorie-Anna Dueck  1 , Bryan Brunet  1 , Donald Gardiner  1 , Shahid Ahmed  1
Affiliations

Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience

Adnan Zaidi et al. Curr Oncol. .

Abstract

Background: The standard approaches for resectable stomach cancer are postoperative chemoradiotherapy (PCR) or perioperative chemotherapy (PC). Limited evidence is available regarding the superiority of one of the two approaches. We aimed to compare the survival of patients with operable stomach cancer who were treated with PC or PCR.

Methods: In this retrospective cohort study, patients with operable stomach cancer diagnosed between 2005-2015 in the province of Saskatchewan were identified and, based on type of treatment, were placed into PCR and PC groups. A Cox proportional multivariate analysis was performed to assess independent prognostic variables, including survival advantage of PC over PCR.

Results: A total of 88 eligible patients with a median age of 66 (56-71) and a male to female ratio of 1:0.44 were identified. Seventy-three (83%) patients had pathologically node positive disease. Sixty-seven (76%) patients received PCR, while 21 (24%) patients received PC. The median overall survival of the whole group was 34 months, with 38 months (95% CI 24.6-51.3) in the PCR group vs. 30 months (14.3-45.7) in the PC group (p = 0.29). Median relapse-free survival was 34 months (20.7-47.3) in the PCR group vs. 23 months (6.7-39.3) in the PC group (p = 0.20). Toxicities were comparable. On multivariate analysis, T ≥ 3 tumor (HR, 3.57 (1.39-8.56)), neutrophil to lymphocyte ratio (LNR) > 2.8 (HR, 1.85 (1.05-3.25)), and positive resection margins (HR, 1.89 (1.06-3.37)) were independently correlated with inferior survival.

Conclusions: This well-designed population based cohort study suggests a lack of survival benefit of PC over PCR. Both treatment options remain viable approaches for resectable stomach cancer.

Keywords: neutrophil to lymphocyte ratio; perioperative chemotherapy; postoperative chemoradiotherapy; stomach cancer.

PubMed Disclaimer

Conflict of interest statement

No author has any conflict of interest to report.

Figures

Figure 1
Figure 1
Flow chart showing eligible patients.
Figure 2
Figure 2
(A): Kaplan-Meier relapse-free survival curves of two groups: patients who were treated with perioperative chemotherapy compared to those who received adjuvant chemoradiotherapy. (B): Kaplan-Meier overall survival curves of two groups: patients who were treated with perioperative chemotherapy compared to those who received adjuvant chemoradiotherapy.
Figure 2
Figure 2
(A): Kaplan-Meier relapse-free survival curves of two groups: patients who were treated with perioperative chemotherapy compared to those who received adjuvant chemoradiotherapy. (B): Kaplan-Meier overall survival curves of two groups: patients who were treated with perioperative chemotherapy compared to those who received adjuvant chemoradiotherapy.
See this image and copyright information in PMC

References

    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Ferlay J., Shin H., Bray F., Forman D., Mathers C., Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency Research Cancer; Lyon, France: 2010.
    1. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani A.J., Gunderson L.L., Jessup J.M., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001;345:725–730. doi: 10.1056/NEJMoa010187. - DOI - PubMed
    1. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J.H., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. - DOI - PubMed

Publication types

LinkOut - more resources